Chen I C, Yang R S, Ou L F, Tang Y W, Jian M J
Department of Surgery, Taichung Veterans General Hospital, Taiwan, ROC.
Zhonghua Yi Xue Za Zhi (Taipei). 1998 Jun;61(6):346-52.
Intra-replant subcutaneous heparin injection has been reported to be an alternative to venous anastomoses in finger replantations. It has also been recommended for composite graft type replants. In this study, we investigated three different regimens of intra-graft heparin injection in a rabbit ear model. Our aim was to determine whether or not continuous oozing from an incision wound on a composite graft made by an intra-graft heparin injection would increase the survival of a larger composite graft.
A 25-mm-diameter circular composite graft (including dorsal skin and auricular cartilage) was harvested from the mid-portion of a rabbit ear. This size of graft was selected as the study model due to a significantly lower percent graft survival when compared to smaller-sized grafts (17.0 +/- 5.6%, p < 0.05). Three different regimens of intra-graft heparin injection were performed in the study group and the results of percent graft survival were compared.
Intra-graft injection of heparin calcium 250 IU/0.1 ml qd for seven days resulted in a significantly higher percent graft survival than the other two regimens and a control group (64.0 +/- 9.7%, p < 0.05). The "flow-through" phenomenon was observed in this study.
Intra-graft heparin injection resulted in a higher percent graft survival than the control group for the 25-mm-diameter circular composite graft. However, the mechanism of graft survival enhancement could not be clearly explained by this study. It is recommended that the clinical application of intra-graft heparin injection should only be used when subgraft hematoma can be avoided and systemic bleeding tendency is being closely monitored.
据报道,指体再植术中移植体内皮下注射肝素可替代静脉吻合。它也被推荐用于复合组织移植类型的再植。在本研究中,我们在兔耳模型中研究了三种不同的移植体内肝素注射方案。我们的目的是确定移植体内肝素注射导致的复合组织移植切口持续渗血是否会提高更大尺寸复合组织移植的存活率。
从兔耳中部获取直径25毫米的圆形复合组织移植块(包括背部皮肤和耳廓软骨)。选择这种尺寸的移植块作为研究模型是因为与较小尺寸的移植块相比,其移植存活率百分比显著更低(17.0±5.6%,p<0.05)。研究组采用三种不同的移植体内肝素注射方案,并比较移植存活率百分比结果。
移植体内注射250国际单位/0.1毫升肝素钙,每日一次,共七天,其移植存活率百分比显著高于其他两种方案及一个对照组(64.0±9.7%,p<0.05)。本研究中观察到了“贯通”现象。
对于直径25毫米的圆形复合组织移植,移植体内注射肝素的移植存活率百分比高于对照组。然而,本研究无法清楚解释移植存活增强的机制。建议仅在能够避免移植块下血肿且密切监测全身出血倾向时,才应用移植体内肝素注射。